Connect to other sites within the UBM Medica Network
METEOR: Cabozantinib Improves Survival in Advanced Kidney Cancer
Cabozantinib significantly delayed progression of disease compared with everolimus in patients with advanced clear cell renal cell carcinoma.
Lenvatinib Plus Everolimus Improves Survival in Metastatic RCC
A combination of lenvatinib plus everolimus improved survival and overall response compared with everolimus alone in metastatic renal cell carcinoma patients.
Oncology Drug Snapshot: Axitinib (Inlyta)
This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Renal Cancer Management in a Patient With Chronic Kidney Disease
A 69-year-old man presented in the urology clinic for evaluation of bilateral renal masses, discovered incidentally during routine exams for follow-up of his chronic kidney disease.
Neutrophil-to-Lymphocyte Ratio Linked to mRCC Outcomes
Metastatic renal cell carcinoma patients with an elevated neutrophil-to-lymphocyte ratio at baseline had inferior outcomes compared to those with a low ratio.
Current Guidelines Miss One-Third of RCC Recurrences
If physicians are following the current NCCN and AUA renal cell carcinoma surveillance guidelines, they could be missing as many as one-third of recurrences.
Smoking May Increase Risk of Second Primary Cancer
Cancer survivors are at an increased risk for developing a second smoking-associated cancer if they smoked cigarettes prior to their first cancer diagnosis.
By clicking Accept, you agree to become a member of the UBM Medica Community.